Maxim Biomedical
PrivateLast Round
Private Equity
Jul 29, 2024
Total Funding Raised
$62.31M
Company Overview
Maxim Biomedical operates in Healthcare & Life Sciences and is based in Rockville, Maryland. Its latest recorded funding round was a Private Equity round in July 2024.
Maxim Biomedical is a biotechnology company that develops and manufactures in vitro diagnostic and point-of-care testing solutions.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Smart Manufacturing
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts, Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Maxim Biomedical Comparables
Compare Maxim Biomedical with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| InBios International, Inc. | 82% | |
| DCN Diagnostics | 81% | |
| Abingdon Health Plc | 79% |
For institutional investors. Book with your work email.
Maxim Biomedical Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Equity | Jul 29, 2024 | ||||
| Grant | Feb 1, 2024 | ||||
| Grant | Jan 4, 2024 | ||||
| Grant | May 9, 2023 | ||||
| Grant | Sep 2, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Maxim Biomedical Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute of Biomedical Imaging and Bioengineering | Grant |
| CTM Investments | Private Equity |
| Administration for Strategic Preparedness and Response | Grant |
| U.S. Department of Health and Human Services | Grant |
| NIH RADx | Grant |
| Administration for Strategic Preparedness and Response | Grant |
| Launch Capital | Private Equity |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 1, 2024
$4.4M grant from NIH RADx and HHS.
- Jan 4, 2024
$50M grant from U.S. Department of Health and Human Services.
For institutional investors. Book with your work email.
Maxim Biomedical Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Maxim Biomedical's valuation, stock price, and market status.
Is Maxim Biomedical a public or private company?
Maxim Biomedical is a private company.
What is the current stock price of Maxim Biomedical?
Maxim Biomedical is a private company, so its shares have no public market price. Caplight tracks Maxim Biomedical's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Maxim Biomedical worth (valuation)?
Valuation information for Maxim Biomedical is not publicly available.
Can I buy Maxim Biomedical stock?
Maxim Biomedical shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Maxim Biomedical's last funding round?
Maxim Biomedical's most recent funding round was Private Equity on July 29, 2024.
Who are the main investors in Maxim Biomedical?
Key investors in Maxim Biomedical include CTM Investments.
Will Maxim Biomedical IPO soon?
No public IPO plans have been announced for Maxim Biomedical.
How can I track Maxim Biomedical secondary market activity?
Caplight tracks bids, offers, and trades in Maxim Biomedical's shares on secondary markets.